|Mr. Richard C. Williams||Chairman and Consultant||128k||N/A||73|
|Dr. Dennis J. Carlo Ph.D.||Chief Exec. Officer, Pres and Director||746.28k||N/A||74|
|Mr. Robert O. Hopkins||Chief Financial Officer, VP of Fin. and Sec.||369.98k||N/A||57|
|Mr. David J. Marguglio||Chief Bus. Officer, Sr. VP and Director||395.53k||N/A||47|
|Mr. Robert B. Rothermel||Consultant and Director||64k||N/A||73|
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The companys specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Adamis Pharmaceuticals Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.